Hand-Foot Syndrome - 14 Studies Found
| Completed |
: Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome :
: 2010-04-06 :
|
| No longer available |
: A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer : the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine : 2012-06-21 :
|
| Active, not recruiting |
: Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer :
|
| Completed |
: F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer :
: 2009-10-08 :
|
| Completed |
: Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer :
|
| Completed |
: Eniluracil Hand Foot Syndrome :
: 2009-01-22 :
|
| Completed |
: Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail : Hepatocellular Carcinoma : 2016-11-06 :
|
| Completed |
: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine). : Breast Cancer : 2008-04-16 :
|
| Completed |
: Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED) : Ovarian Neoplasms : 2008-08-26 : Drug: Caelyx (Pegylated Lyposomal Doxorubicin) Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks f |
| Completed |
: Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer :
|